BOSTON, Nov. 7, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, today announced the company will deliver poster ...
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical ...
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, ...
Dong-A ST announced on April 28 that it will present preclinical results of 'SC2073 (IN-207039)', an EGFR (epidermal growth factor receptor) targeted protein degrader currently under joint research ...
The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, a clinical-stage ...
- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO ®), second line therapy Dato-DXd (Trop-2 ADC DATROWAY ®) ...
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the “Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline ...
DF9001 is currently being evaluated for the treatment of Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Head and Neck Squamous Cell Carcinoma DF6215 is currently being evaluated for the ...
SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, a clinical-stage biopharmaceutical company focused on the design and development of next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback